Cholangiocarcinoma-UK
Mission Statement
Cholangiocarcinoma-UK, an affiliate of the British Association for Study of Liver Disease (BASL), is a multi-disciplinary Special Interest Group (SIG) of clinicians, scientists and patient advocates whose purpose is to facilitate collaborative research, enhance service development and raise awareness of Cholangiocarcinoma.
Aims of Cholangiocarcinoma UK
• Be the recognised leading authority on Cholangiocarcinoma in the UK
• Become affiliated to other relevant major national organisations e.g. BASO, BSG
• Facilitate basic science and clinical research as well as sample collection, including for biomarker development
• Improve the pathway to collaborative clinical trials and opportunities for research funding
• Update national guidelines and advise on policy and best practice
• Optimise and standardise clinical management across the country
• Monitor epidemiological trends accurately.
Steering Committee
Chair | Professor Shahid Khan | Imperial College, London |
Deputy chair/secretary | TBC | |
Patient advocate | Helen Morement | AMMF – The Cholangiocarcinoma Charity |
Basic science representatives | Professor David Bates | University of Nottingham |
Dr Luke Boulter | MRC Human Genetics Unit, Edinburgh | |
Dr Chiara Braconi | University of Glasgow | |
Dr Sheela Jayaraman | University of Birmingham | |
Endoscopy representative | Professor Steve Pereira | University College / Royal Free Hospital, London |
Hepatology representative | Dr Simon Rushbrook | Norfolk & Norwich University Hospitals |
Clinical oncology representative | Professor Maria Hawkins | University College, London |
Medical oncology representatives | Professor John Bridgewater | University College, London |
Professor Juan Valle | Christie NHS Foundation Trust / University of Manchester | |
Pathology representative | Dr Tim Kendall | University of Edinburgh / Royal Infirmary Edinburgh |
Surgery representatives | Professor Brian Davidson | Royal Free Hospital, London |
Professor Nigel Heaton | King's College Hospital, London | |
Mr Hassan Malik | Aintree University Hospital | |
Trainee representatives | Dr Pilar Acedo | University College, London |
Dr Leonard Marc Quinn | University of Liverpool | |
Dr Isioma Egbuniwe | University of Nottingham |
Resources
Annual reports
Annual report 2018-19 - .
1st meeting - 7 December 2018
Report -.
Welcome presentation, Shahid Khan, St Mary’s Hospital, London -
Presentation on the patient/healthcare professional partnership, Helen Morement, AMMF -
Presentation on Epidemiology and aetiology: What we don’t know & how can we find out, Shahid Khan, St Mary’s Hospital, London -
Presentation on Ensuring quality: Centres of “excellence/expertise”?, Hassan Malik, Aintree University Hospital
Presentation on Medical oncology: The unmet needs and how we meet them, John Bridgewater, UCL & Juan Valle, Christie NHS Foundation Trust -
Presentation on Clinical oncology: Establishing novel roles in CCA therapy, Maria Hawkins, University of Oxford -
2nd meeting - 14 November 2019
Presentation on Cholangiocarcinoma and liver fluke infection in Lao PDR, Peter Odermatt, Swiss Tropical and Public Health Institute -
Presentation on Universal tumour antigens in primary liver cancers: Cholangiocarcinoma and Hepatocellular carcinoma are differentUniversal tumour antigens in primary liver cancers: Cholangiocarcinoma and Hepatocellular carcinoma are different, Ollie Rupar, University of Plymouth -
Presentation on Single molecule detection of osteopontin in nanopores using DNA molecular carriers, Micol Damiani, Imperial College London -
Presentation on the investigation of virus-driven intrahepatic Cholangiocarcinoma through dysregulated hepatic differentiation, Alex Kilvington, University of Leeds -
Presentation on the role of mesenchymalcells in Cholangiocarcinoma, Mireia Sueca Comes, University of Nottingham -
Presentation on non-coding RNAs and the biology underpinning potential new precision medicines in Cholangiocarcinoma, Chiara Braconi, University of Glasgow -
Presentation on Delphi process on next key questions in basic science of Cholangiocarcinoma, Shahid Khan, Imperial College London -
Patient representation
The AMMF is represented on the CCA-UK Steering Committee and is the UK’s only cholangiocarcinoma charity - .
Global CCA Alliance
The Global Cholangiocarcinoma Alliance (GCA) has united to establish a global voice in CCA through community collaborations. The GCA has a shared vision to raise the awareness of CCA, in order to improve prevention, survival and the quality of life of CCA patients globally. CCA-UK is a partner in this Alliance. For more information, visit .
Cholangiocarcinoma-UK 2025 Conference: Abstract Submission & Registration Open
Date: 1st & 2nd December 2025
Venue: The Jubilee Hotel & Conferences, Nottingham
Registration is now open!
This will be the UK's largest multi-disciplinary meeting dedicated to cholangiocarcinoma research, bringing together clinical and preclinical researchers for two days of collaboration, innovation, and progress in bile duct cancer.
The programme will feature national and international speakers, cutting-edge research and dedicated sessions on the molecular biology of cholangiocarcinoma, the role of the tumour microenvironment, translation research, and the sharing of samples and resources.
Register by clicking > or via the QR Code below:
Abstract submissions are now open!
We invite contributions from across the cholangiocarcinoma research community, that advance our understanding of cholangiocarcinoma and translational opportunities.
Submission Âé¶¹´«Ã½: Monday October 20th 2025
Submit your abstract by clicking > or via the QR Code below:
Please see the Abstract Guidance here>
Conference Highlights:
Keynote Speaker: We’re honoured to welcome Professor Jesús Bañales, a leading expert in liver disease and cholangiocarcinoma
Sessions:
Understanding Cholangiocarcinoma
New Approaches to Diagnosis and Treatment
Increasing Collaboration and Data/Sample Sharing – Includes a round table discussion featuring five contributors exploring cross-disciplinary partnerships
Vaccines and the Immune Response
Programme:
View the Programme for 1st December > HERE
View the Programme for 2nd December > HERE
Neil Blenkinsop Pump Priming Award 2025:
Applications Open
Applications Close 1st November
Be part of the conversation shaping the future of Cholangiocarcinoma research and care.
We look forward to welcoming you to what is sure to be an insightful and impactful event!
Contact cca-uk@basl.org.uk for any queries.